{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T08:40:27Z","timestamp":1776933627701,"version":"3.51.2"},"reference-count":49,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2019,2,18]],"date-time":"2019-02-18T00:00:00Z","timestamp":1550448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Trastuzumab is a milestone in the treatment of human epidermal growth factor receptor 2 positive (HER2+) breast cancer (BC), in both the early and metastatic settings. Over the last two decades, clinical trials have established the good safety profile of trastuzumab. Cardiotoxicity remains the most frequent adverse event, more commonly exemplified by an asymptomatic decline in the left ventricular ejection fraction rather than congestive heart failure. Results from several long-term (&gt;5 years) safety analyses have been recently published, with the inherent evidence substantially confirming the findings from previous trials. The clinical experience gained over the years in the use of trastuzumab has also fueled a number of observational studies focused on the effectiveness of this drug in the real-world settings. We herein reviewed the evidence available from tree major databases, namely, PubMed, EMBASE and the Cochrane Central Register of Controlled Trials (CENTRAL), to explore and critically discuss key issues related to the long-term safety and effectiveness of trastuzumab in clinical practice.<\/jats:p>","DOI":"10.3390\/jcm8020254","type":"journal-article","created":{"date-parts":[[2019,2,19]],"date-time":"2019-02-19T04:08:20Z","timestamp":1550549300000},"page":"254","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Long-Term Safety and Real-World Effectiveness of Trastuzumab in Breast Cancer"],"prefix":"10.3390","volume":"8","author":[{"given":"Marco","family":"Mazzotta","sequence":"first","affiliation":[{"name":"Department of Clinical and Molecular Medicine, \u201cSapienza\u201d University of Rome, Azienda Ospedaliera Sant\u2019Andrea, 00189 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eriseld","family":"Krasniqi","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi, 53, 00144 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Barchiesi","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi, 53, 00144 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Pizzuti","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi, 53, 00144 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Tomao","sequence":"additional","affiliation":[{"name":"Department of Gynecology-Obstetrics and Urology, \u201cSapienza\u201d University of Rome, 00161 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maddalena","family":"Barba","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi, 53, 00144 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Vici","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi, 53, 00144 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,2,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3816\/CBC.2004.n.011","article-title":"HER2amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues","volume":"5","author":"Owens","year":"2004","journal-title":"Clin. Breast Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Viani, G.A., Afonso, S.L., Stefano, E.J., De Fendi, L.I., and Soares, F.V. (2007). Adjuvant trastuzumab in the treatment of HER2-positive early breast cancer: A meta-analysis of published randomized trials. BMC Cancer, 7.","DOI":"10.1186\/1471-2407-7-153"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1200\/jco.2013.31.15_suppl.629","article-title":"Double-blind, randomized, parallel group, phase III study to demonstrate equivalent efficacy and comparable safety of CT-P6 and trastuzumab, both in combination with paclitaxel, in patients with metastatic breast cancer (mbc) as first-line treatment","volume":"31","author":"Im","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1200\/JCO.2017.35.15_suppl.510","article-title":"Double-blind, randomized phase III study to compare the efficacy and safety of CT-P6 trastuzumab biosimilar candidate versus trastuzumab as neoadjuvant treatment in her2 positive early breast cancer (ebc)","volume":"35","author":"Stebbing","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","article-title":"11 years\u2019 follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: Final analysis of the HERceptin Adjuvant (HERA) trial","volume":"389","author":"Cameron","year":"2017","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s00432-013-1436-y","article-title":"Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer","volume":"139","author":"Natoli","year":"2013","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"v43","DOI":"10.1093\/annonc\/mdx362.025","article-title":"OHERA: A real world study of cardiac events in\u2009>3700 patients with her2-positive early breast cancer treated with trastuzumab: Final analysis","volume":"28","author":"Lidbrink","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Goldhar, H.A., Yan, A.T., Ko, D.T., Earle, C.C., Tomlinson, G.A., Trudeau, M.E., Krahn, M.D., Krzyzanowska, M.K., Pal, R.S., and Brezden-Masley, C. (2015). The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study. J. Natl. Cancer Inst., 108.","DOI":"10.1093\/jnci\/djv301"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1634\/theoncologist.2015-0230","article-title":"Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium","volume":"21","author":"Seferina","year":"2016","journal-title":"Oncologist"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.breast.2015.02.035","article-title":"Long term HER2+ metastatic breast cancer survivors treated by trastuzumab: Results from the French cohort study LHORA","volume":"24","author":"Spano","year":"2015","journal-title":"Breast"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2015.09.012","article-title":"Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival","volume":"52","author":"Rossi","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"M\u00fcller, V., Clemens, M., Jassem, J., Al-Sakaff, N., Auclair, P., N\u00fcesch, E., Holloway, D., Shing, M., and Bang, Y.-J. (2018). Long-term trastuzumab (Herceptin\u00ae) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4183-2"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.breast.2015.09.008","article-title":"Long-term outcome of HER2 positive metastatic breast cancer patients treated with first-line trastuzumab","volume":"24","author":"Yeo","year":"2015","journal-title":"Breast"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.18632\/oncotarget.13726","article-title":"Long-term tolerance and cardiac function in breast cancer patients receiving trastuzumab therapy","volume":"8","author":"Huang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5035","DOI":"10.12659\/MSM.898807","article-title":"Evaluation of Left Ventricular Ejection Fractions in Breast Cancer Patients Undergoing Long-Term Trastuzumab Treatment","volume":"22","author":"Sun","year":"2016","journal-title":"Med. Sci. Monit."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1634\/theoncologist.2015-0006","article-title":"Real-Life Use and Effectiveness of Adjuvant Trastuzumab in Early Breast Cancer Patients: A Study of the Southeast Netherlands Breast Cancer Consortium","volume":"20","author":"Seferina","year":"2015","journal-title":"Oncologist"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4103\/0971-5851.203511","article-title":"Treatment Challenges and Survival Analysis of Human Epidermal Growth Factor Receptor 2-positive Breast Cancer in Real World","volume":"38","author":"Adusumilli","year":"2017","journal-title":"Indian J. Med. Paediatr. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s10549-014-3133-1","article-title":"Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: A real-world multicenter observational analysis. The RETROHER study","volume":"147","author":"Vici","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"17932","DOI":"10.18632\/oncotarget.7480","article-title":"Triple positive\" early breast cancer: An observational multicenter retrospective analysis of outcome","volume":"7","author":"Vici","year":"2016","journal-title":"Oncotarget"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.2217\/fon.15.34","article-title":"Observational study on adjuvant trastuzumab in HER2-positive early breast cancer patients","volume":"11","author":"Mustacchi","year":"2015","journal-title":"Future Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Gori, S., Inno, A., Fiorio, E., Foglietta, J., Ferro, A., Gulisano, M., Pinotti, G., Gubiotti, M., Cavazzini, M.G., and Turazza, M. (2015). The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0139650"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s10549-014-2907-9","article-title":"Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: A multicenter retrospective observational study (JBCRG-C03 study)","volume":"145","author":"Takada","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1634\/theoncologist.2016-0193","article-title":"Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany","volume":"22","author":"Dall","year":"2017","journal-title":"Oncologist"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.breast.2017.11.007","article-title":"Trastuzumab for metastatic breast cancer: Real world outcomes from an Australian whole-of-population cohort (2001-2016)","volume":"38","author":"Daniels","year":"2018","journal-title":"Breast"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10549-018-4804-0","article-title":"Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: Real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001\u20132016)","volume":"171","author":"Daniels","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s40273-016-0411-2","article-title":"Real-World Evidence: A Comparison of the Australian Herceptin Program and Clinical Trials of Trastuzumab for HER2-Positive Metastatic Breast Cancer","volume":"34","author":"Parkinson","year":"2016","journal-title":"PharmacoEconomics"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1634\/theoncologist.2012-0414","article-title":"First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER","volume":"18","author":"Tripathy","year":"2013","journal-title":"Oncologist"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s10549-012-2209-z","article-title":"Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study","volume":"135","author":"Kaufman","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1634\/theoncologist.2017-0088","article-title":"Disparities of Trastuzumab Use in Resource-Limited or Resource-Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real-World Study from China","volume":"22","author":"Li","year":"2017","journal-title":"Oncologist"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1200\/JCO.2009.23.6950","article-title":"Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: A combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials","volume":"28","author":"Russell","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.tips.2015.03.005","article-title":"Anthracyclines\/trastuzumab: New aspects of cardiotoxicity and molecular mechanisms","volume":"36","author":"Rochette","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1517\/14740331003627441","article-title":"The cardiac safety of trastuzumab in the treatment of breast cancer","volume":"9","author":"Chien","year":"2010","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_36","first-page":"70","article-title":"Trastuzumab-induced cardiac dysfunction: A \u201cdual-hit\u201d","volume":"16","author":"Zeglinski","year":"2011","journal-title":"Exp. Clin. Cardiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Procter","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1200\/JCO.2013.53.9288","article-title":"Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01)","volume":"32","author":"Procter","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1200\/JCO.2011.40.0010","article-title":"Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer","volume":"30","author":"Romond","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1200\/JCO.2017.74.1165","article-title":"Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31\/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2","volume":"35","author":"Ganz","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1200\/JCO.2015.61.8413","article-title":"Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial","volume":"34","author":"Advani","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"5685","DOI":"10.1200\/JCO.2008.21.4577","article-title":"Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: Final results of the FinHer Trial","volume":"27","author":"Joensuu","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1200\/JCO.2005.07.032","article-title":"Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer","volume":"23","author":"Buzdar","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/cncr.22895","article-title":"Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: A retrospective review of the M. D. Anderson experience","volume":"110","author":"Dawood","year":"2007","journal-title":"Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1002\/jcp.25432","article-title":"Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial","volume":"231","author":"Pizzuti","year":"2016","journal-title":"J. Cell. Physiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1200\/JCO.2010.31.4930","article-title":"Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: Results from the TECHNO trial of the AGO and GBG study groups","volume":"29","author":"Untch","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0140-6736(09)61964-4","article-title":"Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): A randomised controlled superiority trial with a parallel HER2-negative cohort","volume":"375","author":"Gianni","year":"2010","journal-title":"Lancet"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1200\/JCO.2009.23.8451","article-title":"Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: Results from the GeparQuattro study","volume":"28","author":"Untch","year":"2010","journal-title":"J. Clin. Oncol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/8\/2\/254\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:32:51Z","timestamp":1760185971000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/8\/2\/254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,18]]},"references-count":49,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,2]]}},"alternative-id":["jcm8020254"],"URL":"https:\/\/doi.org\/10.3390\/jcm8020254","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,18]]}}}